Akebia: CMS grants TDAPA reimbursement for Vafseo starting January 1, 2025

Akebia Therapeutics announced that the Center for Medicare & Medicaid Services has determined that Vafseo meets the criteria for the Transitional Drug Add-On Payment Adjustment in the anemia management end-stage renal disease prospective payment system functional category, beginning on January 1, 2025. In March 2024, Vafseo was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and the product is expected to be available in the market in January 2025. The TDAPA program provides two years of reimbursement for Vafseo in addition to the ESRD bundled rate to dialysis organizations. Additionally, Akebia received a Level II Healthcare Common Procedure Coding System code for Vafseo which will be used for billing for the product by dialysis organizations for Medicare enrollees. Within the next several weeks, CMS is expected to issue a Medicare Claims Processing Change Request that will give further billing guidance to dialysis organizations to obtain the separate TDAPA payment for the next two years under Medicare.